Acute lymphoblastic leukemia, version 2.2021

Patrick A. Brown; Bijal Shah; Anjali Advani; Patricia Aoun; Michael W. Boyer; Patrick W. Burke; Daniel J. DeAngelo; Shira Dinner; Amir T. Fathi; Jordan Gauthier; Nitin Jain; Suzanne Kirby; Michaela Liedtke; Mark Litzow; Aaron Logan; Selina Luger; Lori J. Maness; Stephanie Massaro; Ryan J. Mattison; William May; Olalekan Oluwole; Jae Park; Amanda Przespolewski; Sravanti Rangaraju; Jeffrey E. Rubnitz; Geoffrey L. Uy; Madhuri Vusirikala; Matthew Wieduwilt; Beth Lynn; Ryan A. Berardi; Deborah A. Freedman-Cass; Mallory Campbell

doi:10.6004/jnccn.2021.0042

Acute lymphoblastic leukemia, version 2.2021

Patrick A. Brown, Bijal Shah, Anjali Advani, Patricia Aoun, Michael W. Boyer, Patrick W. Burke, Daniel J. DeAngelo, Shira Dinner, Amir T. Fathi, Jordan Gauthier, Nitin Jain, Suzanne Kirby, Michaela Liedtke, Mark Litzow, Aaron Logan, Selina Luger, Lori J. Maness, Stephanie Massaro, Ryan J. Mattison, William MayOlalekan Oluwole, Jae Park, Amanda Przespolewski, Sravanti Rangaraju, Jeffrey E. Rubnitz, Geoffrey L. Uy, Madhuri Vusirikala, Matthew Wieduwilt, Beth Lynn, Ryan A. Berardi, Deborah A. Freedman-Cass, Mallory Campbell

Research output: Contribution to journal › Review article › peer-review

122 Scopus citations

Abstract

The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients; and supportive care considerations. Given the complexity of ALL treatment regimens and the required supportive care measures, the NCCN ALL Panel recommends that patients be treated at a specialized cancer center with expertise in the management of ALL This portion of the Guidelines focuses on the management of Ph-positive and Ph-negative ALL in adolescents and young adults, and management in relapsed settings.

Original language	English
Pages (from-to)	1079-1109
Number of pages	31
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	19
Issue number	9
DOIs	https://doi.org/10.6004/jnccn.2021.0042
State	Published - Sep 2021

Access to Document

10.6004/jnccn.2021.0042

Cite this

Brown, P. A., Shah, B., Advani, A., Aoun, P., Boyer, M. W., Burke, P. W., DeAngelo, D. J., Dinner, S., Fathi, A. T., Gauthier, J., Jain, N., Kirby, S., Liedtke, M., Litzow, M., Logan, A., Luger, S., Maness, L. J., Massaro, S., Mattison, R. J., ... Campbell, M. (2021). Acute lymphoblastic leukemia, version 2.2021. JNCCN Journal of the National Comprehensive Cancer Network, 19(9), 1079-1109. https://doi.org/10.6004/jnccn.2021.0042

@article{dc92f522fc0245589b3fb754f46b6286,

title = "Acute lymphoblastic leukemia, version 2.2021",

abstract = "The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients; and supportive care considerations. Given the complexity of ALL treatment regimens and the required supportive care measures, the NCCN ALL Panel recommends that patients be treated at a specialized cancer center with expertise in the management of ALL This portion of the Guidelines focuses on the management of Ph-positive and Ph-negative ALL in adolescents and young adults, and management in relapsed settings.",

author = "Brown, {Patrick A.} and Bijal Shah and Anjali Advani and Patricia Aoun and Boyer, {Michael W.} and Burke, {Patrick W.} and DeAngelo, {Daniel J.} and Shira Dinner and Fathi, {Amir T.} and Jordan Gauthier and Nitin Jain and Suzanne Kirby and Michaela Liedtke and Mark Litzow and Aaron Logan and Selina Luger and Maness, {Lori J.} and Stephanie Massaro and Mattison, {Ryan J.} and William May and Olalekan Oluwole and Jae Park and Amanda Przespolewski and Sravanti Rangaraju and Rubnitz, {Jeffrey E.} and Uy, {Geoffrey L.} and Madhuri Vusirikala and Matthew Wieduwilt and Beth Lynn and Berardi, {Ryan A.} and Freedman-Cass, {Deborah A.} and Mallory Campbell",

year = "2021",

month = sep,

doi = "10.6004/jnccn.2021.0042",

language = "English",

volume = "19",

pages = "1079--1109",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

number = "9",

}

Brown, PA, Shah, B, Advani, A, Aoun, P, Boyer, MW, Burke, PW, DeAngelo, DJ, Dinner, S, Fathi, AT, Gauthier, J, Jain, N, Kirby, S, Liedtke, M, Litzow, M, Logan, A, Luger, S, Maness, LJ, Massaro, S, Mattison, RJ, May, W, Oluwole, O, Park, J, Przespolewski, A, Rangaraju, S, Rubnitz, JE, Uy, GL, Vusirikala, M, Wieduwilt, M, Lynn, B, Berardi, RA, Freedman-Cass, DA & Campbell, M 2021, 'Acute lymphoblastic leukemia, version 2.2021', JNCCN Journal of the National Comprehensive Cancer Network, vol. 19, no. 9, pp. 1079-1109. https://doi.org/10.6004/jnccn.2021.0042

TY - JOUR

T1 - Acute lymphoblastic leukemia, version 2.2021

AU - Brown, Patrick A.

AU - Shah, Bijal

AU - Advani, Anjali

AU - Aoun, Patricia

AU - Boyer, Michael W.

AU - Burke, Patrick W.

AU - DeAngelo, Daniel J.

AU - Dinner, Shira

AU - Fathi, Amir T.

AU - Gauthier, Jordan

AU - Jain, Nitin

AU - Kirby, Suzanne

AU - Liedtke, Michaela

AU - Litzow, Mark

AU - Logan, Aaron

AU - Luger, Selina

AU - Maness, Lori J.

AU - Massaro, Stephanie

AU - Mattison, Ryan J.

AU - May, William

AU - Oluwole, Olalekan

AU - Park, Jae

AU - Przespolewski, Amanda

AU - Rangaraju, Sravanti

AU - Rubnitz, Jeffrey E.

AU - Uy, Geoffrey L.

AU - Vusirikala, Madhuri

AU - Wieduwilt, Matthew

AU - Lynn, Beth

AU - Berardi, Ryan A.

AU - Freedman-Cass, Deborah A.

AU - Campbell, Mallory

PY - 2021/9

Y1 - 2021/9

N2 - The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients; and supportive care considerations. Given the complexity of ALL treatment regimens and the required supportive care measures, the NCCN ALL Panel recommends that patients be treated at a specialized cancer center with expertise in the management of ALL This portion of the Guidelines focuses on the management of Ph-positive and Ph-negative ALL in adolescents and young adults, and management in relapsed settings.

AB - The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients; and supportive care considerations. Given the complexity of ALL treatment regimens and the required supportive care measures, the NCCN ALL Panel recommends that patients be treated at a specialized cancer center with expertise in the management of ALL This portion of the Guidelines focuses on the management of Ph-positive and Ph-negative ALL in adolescents and young adults, and management in relapsed settings.

UR - http://www.scopus.com/inward/record.url?scp=85116020361&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2021.0042

DO - 10.6004/jnccn.2021.0042

M3 - Review article

C2 - 34551384

AN - SCOPUS:85116020361

SN - 1540-1405

VL - 19

SP - 1079

EP - 1109

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 9

ER -

Acute lymphoblastic leukemia, version 2.2021

Abstract

Access to Document

Other files and links

Fingerprint

Cite this